EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comOver the last few decades, drug discovery developments have radically changed the face of medicine practice. The advent of cutting-edge molecular biology methods has further changed the paradigm into a hypothesis-driven target-based approach. Amidst these, for translating the basic science into new medical treatments for unmet medical needs, today academia, the regulatory agencies, and the pharmaceutical industry all contribute their knowledge for constant development of this space. However, the costly nature of drug development often undermines the growth of this industry with pharmaceutical manufacturers making large investments in R&D over long periods along with relying on fundamental research carried out in universities and other research organizations.Among the most significant causes of late-drug failure is the lack of efficiency in phase II and phase trials along with the increasing security concerns. As a result, the pharmaceutical industry has been seeking for improved and pertinent cellular models that can supplement the efficacy of trails. Next, it also becomes a tedious task for pharmaceutical manufacturers to garner an adequate amount of primary human cells for accelerating the drug discovery programs. Apart from the source of cells, the other major issue in vitro cell culture is that 2D cell culture systems do not reflect the environment that a cell can experience with the 3D organism. To assist industry leaders to maneuver in the right direction while adopting drug discovery and development solutions, our distinguished editorial panel at Pharma Tech Outlook have analyzed the different emerging trends in the drug discovery and development space to filter out solutions that are genuinely crafted for this space, outperform others, and can solve the imperative challenges prevailing in the industry. This edition of our magazine is a result of our commitment to stick to our mission. We bring you the "Top 10 Drug Discovery and Development Solution Providers in Europe ­ 2019." Please let us know your thoughts.The Imperative Role of Technology in Drug DevelopmentsCopyright © 2019 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.APRIL - 29 - 2019, Vol 05 - Issue 06 Published by ValleyMedia Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasJoshua ParkerJustin SmithSwayamsidha BeheraSalesJennifer Stephen Jennifer@pharmatechoutlook.comPhone: 510.996.5173sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405AR RamjithTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >